USPTO serial 88811637
TRIGENESIS
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- AIKENS, RONALD E
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with TRIGENESIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Paul C. Llewellyn
Paul C. Llewellyn ARNOLD & PORTER KAYE SCHOLER LLP250 WEST 55TH STREETNEW YORK, NY 10019-9710UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform; Pharmaceutical preparations that modulate RNA expression; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products for the treatment of genetic disorders and diseases | ACTIVE | — |
| 016 | Printed materials, namely, brochures, leaflets, reports, and newsletters on the topics of medicine, medical research, scientific research, research and development of pharmaceuticals, biological preparations and gene therapy products, rare and infectious diseases, neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, genetic therapy research, and diagnosis and treatment of genetic disorders | ACTIVE | — |
| 042 | Medical research; medical and scientific research services all in the field of rare and infectious diseases; medical and scientific research services all in the field of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, and genetic diseases and disorders; medical and scientific research services all in the field of gene therapy, gene editing, genome editing, viruses, viral vectors, and viral constructs | ACTIVE | — |
| 044 | Medical information services, namely, providing information relating to of medicine, medical research, scientific research, research and development of pharmaceuticals, biological preparations and gene therapy products, rare and infectious diseases, neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, genetic therapy research, and diagnosis and treatment of genetic disorders; Providing a website and information in the field of medicine, medical research, scientific research, research and development of pharmaceuticals, biological preparations and gene therapy products, rare and infectious diseases, neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, genetic therapy research, and diagnosis and treatment of genetic disorders; Provision of health care services, namely, providing information to doctors and patients regarding rare diseases, medicines, health conditions and treatment options | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Sarepta Therapeutics, Inc.
- Other trademarks owned by Sarepta Therapeutics, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 016
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named TRIGENESIS
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 17, 2023 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jan 16, 2023 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 15, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 13, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jun 13, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jun 13, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 4, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 2, 2021 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Dec 2, 2021 | EXT3 | SOU EXTENSION 3 FILED | — |
| Dec 2, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 20, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 18, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| May 18, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| May 18, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 10, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 8, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 8, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 8, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 16, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 21, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 21, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 1, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 13, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 13, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 6, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 5, 2020 | NWAP | NEW APPLICATION ENTERED | — |